Drug intelligence / Profile preview

MDX2301

Development stage: Phase 1
Lead developer: ModeX Therapeutics
Modality: Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous, Intramuscular, Subcutaneous

Overview

MDX2301 is a multispecific antibody developed by ModeX Therapeutics, a subsidiary of OPKO Health, for the treatment and prevention of COVID-19. Utilizing ModeX's proprietary MSTAR platform, MDX2301 is engineered to bind simultaneously to multiple distinct epitopes on the SARS-CoV-2 spike protein. This multispecific approach is intended to provide broad-spectrum neutralization against a wide range of viral variants and to increase the genetic barrier against viral escape. The development of MDX2301 is supported by a collaboration with the Biomedical Advanced Research and Development Authority (BARDA).

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on MDX2301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MDX2301.

Explore the full profile